National Eye Institute (NEI) scientists have found that the way the retina metabolizes glucose directly controls which genes get switched on and off in light-sensing photoreceptors. The findings ...
Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced updates to its Retina Scientific Advisory Board and Executive Leadership Team. These changes are ...
Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with ...
The data highlight emerging evidence that Opus Genetics’ gene therapy OPGx-LCA5 may restore daytime vision mediated by cones ...
In a recent study published in the journal NPJ Digital Medicine, researchers have developed a deep learning algorithm capable of analyzing high-resolution images of retinal vasculature to detect ...
In March 2026, Boehringer Ingelheim achieved a research milestone under the agreement for SZN-413, reflecting a positive outcome of the IND-enabling GLP toxicology study. The Company received a $5.0 ...
MedPage Today on MSN
Vision-threatening forms of diabetic retinal disease have plummeted
Better diabetes medications, better screening, older age at onset of DRD influence 20-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results